A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma

被引：0
|
作者：
Apolo, Andrea Borghese
Parnes, Howard L.
Madan, Ravi Amrit
Gulley, James L.
Wright, John Joseph
Khadar, Kattie
Trepel, Jane B.
Schlom, Jeffrey
Arlen, Philip M.
Merino, Maria
Steinberg, Seth M.
Choyke, Peter L.
Lindenberg, Maria Liza
Kurdziel, Karen A.
Folio, Les
Figg, William Douglas
Agarwal, Piyush K.
Bottaro, Donald P.
Dahut, William L.
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] NCI, Canc Prevent Div, Bethesda, MD 20892 USA
[3] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA
[4] NCI, Rockville, MD USA
[5] NCI, Med Oncol Branch, Bethesda, MD 20892 USA
[6] NCI, Lab Tumor Immunol & Biol, Med Oncol Branch, Bethesda, MD 20892 USA
[7] NCI, NIH, Bethesda, MD 20892 USA
[8] NCI, Biostat & Data Management Sect, CCR, Bethesda, MD 20892 USA
[9] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[10] NCI, Mol Imaging Program, CCR, NIH, Bethesda, MD 20892 USA
[11] NIH, Bethesda, MD 20892 USA
[12] NCI, Mol Pharmacol Sect, NIH, Bethesda, MD 20892 USA
[13] NCI, Urol Oncol Branchd, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4589
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT)
    Winer, Eric P.
    Tolaney, Sara
    Nechushtan, Hovav
    Berger, Raanan
    Kurzrock, Razelle
    Ron, Ilan-Gil
    Schoffski, Patrick
    Awada, Ahmad
    Yasenchak, Christopher A.
    Burris, Howard A.
    Ramies, David A.
    Rafferty, Teresa
    Shen, Xiaodong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] CLINICAL ACTIVITY AND PHARMACOKINETICS (PK) OF CABOZANTINIB (XL184) IN PATIENTS WITH PROGRESSIVE MEDULLARY THYROID CARCINOMA (MTC)
    Cohen, E. E. W.
    Elisei, R.
    Schlumberger, M. J.
    Mueller, S. P.
    Schoeffski, P.
    Brose, M.
    Shah, M.
    Miles, D. R.
    Nguyen, L. T.
    Sherman, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 154 - 155
  • [23] SENSITIVITY OF GLIOBLASTOMA NEUROSPHERES AND ORTHOTOPIC XENOGRAFTS TO CABOZANTINIB (XL184)
    deCarvalho, Ana C.
    Irtenkauf, Susan
    Hasselbach, Laura
    Xin, Hong
    Mikkelsen, Tom
    NEURO-ONCOLOGY, 2012, 14 : 31 - 31
  • [24] Phase 2 results of XL184 in a cohort of patients (pts) with advanced melanoma
    Nechushtan, H.
    Edelman, G.
    Jerusalem, G.
    Gordon, M.
    Kluger, H. M.
    Moussa, A.
    Ron, I.
    Schimmoller, F.
    Shen, X.
    Daud, A.
    EJC SUPPLEMENTS, 2010, 8 (07): : 126 - 127
  • [25] Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with dear cell renal cell carcinoma (METEOR)
    Choueiri, Toni K.
    Escudier, Bernard J.
    Les, Thomas Pow
    Cella, David
    Ru, Qinhua C.
    Scheffold, Christian
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC)
    Apolo, Andrea B.
    Parnes, Howard L.
    Francis, Deneise C.
    Cordes, Lisa M.
    Berninger, Marilise
    Lamping, Elizabeth
    Costello, Rene
    Trepel, Jane B.
    Merino, Maria J.
    Folio, Les
    Lindenberg, Maria Liza
    Figg, William Douglas
    Steinberg, Seth M.
    Wright, John Joseph
    Madan, Ravi Amrit
    Ning, Yangmin M.
    Gulley, James L.
    Bottaro, Donald P.
    Dahut, William L.
    Agarwal, Piyush K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC)
    Apolo, Andrea Borghese
    Parnes, Howard L.
    Madan, Ravi Amrit
    Gulley, James L.
    Wright, John Joseph
    Hoffman-Censits, Jean H.
    Dawson, Nancy Ann
    Trepel, Jane B.
    Khadar, Kattie
    Schlom, Jeffrey
    Merino, Maria
    Raffeld, Mark
    Steinberg, Seth M.
    Choyke, Peter L.
    Lindenberg, Maria Liza
    Folio, Les
    Agarwal, Piyush K.
    Figg, William Douglas
    Bottaro, Donald P.
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [28] A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC)
    Nadal, R.
    Parnes, H. L.
    Francis, D. C.
    Cordes, L. M.
    Berninger, M.
    Costello, R.
    Folio, L.
    Linderberg, M.
    Machado, L.
    Steinberg, S. M.
    Wright, J. J.
    Ning, Y. M.
    Bottaro, D. P.
    Dahut, W. L.
    Apolo, A. B.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] A phase 3 randomized study of cabozantinib (XL184) vs everolimus in subjects with clear cell renal cell carcinoma (METEOR)
    Choueiri, T. K.
    Escudier, B.
    Powles, T.
    Cella, D.
    Lee, Y.
    Laird, D. A.
    Scheffold, C.
    Motzer, R. J.
    BJU INTERNATIONAL, 2013, 112 : 4 - 4
  • [30] Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.
    Hussain, M.
    Smith, M. R.
    Sweeney, C.
    Corn, P. G.
    Elfiky, A.
    Gordon, M. S.
    Haas, N. B.
    Harzstark, A. L.
    Kurzrock, R.
    Lara, P.
    Lin, C.
    Sella, A.
    Small, E. J.
    Spira, A. I.
    Vaishampayan, U. N.
    Vogelzang, N. J.
    Scheffold, C.
    Ballinger, M. D.
    Schimmoller, F.
    Smith, D. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345